Category Archives: Business and Investments

Latest From Business and Investments

BIO Urges Comprehensive Tax Reform

72263479

Earlier this week, the Treasury Department issued a notice of its intent to propose rules to limit corporate inversions. In response, we are urging Congress and the Administration to reform the corporate tax system in order to maintain America’s global competitiveness, sustain and create American jobs, and encourage investments in the United States. The U.S. has one of the highest effective corporate tax rates in the world. Current U.S. corporate tax laws, including the lack Read More >

Business and Investments, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Members of Congress Agree: Reg A+ Rules Need National Standard

Biotech IPOs Infographic

We’ve written before about the importance of implementing Title IV of the JOBS Act (commonly referred to as the “Reg A+” provision) in a way that will best encourage biotech capital formation. BIO President and CEO Jim Greenwood also discussed the issue in an op-ed at Forbes last week. At issue is whether the SEC will set a national standard for the review of Reg A+ offerings or instead subject companies to the labyrinth that Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

NCATS SBIR Announces Funding For Biotechs and Small Business Technology Development

lab_tech

The NIH National Center for Advancing Translational Sciences (NCATS) is seeking qualified applicants for its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. NCATS, which offers $17.6 million annually through these programs, has issued a call for applications for two funding opportunities: Contract funding to support small businesses and venture-backed technology development, due Nov. 5, 2014. Investigator-initiated grant funding,due Dec. 5, 2014. NCATS’ SBIR and STTR programs are engines of innovation Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Investment in NJ Biotech is Way Up

graph

Total funding of New Jersey life sciences companies spiked in 2013 with approximately $900 million in both early and late-stage investments, according to a new report from BioNJ. This figure represents well over 200 percent growth over the prior year. Funding was helped by seven New Jersey companies that completed initial public offerings (IPOs) in 2013. Furthermore, industry wages averaged $126,794 in 2012, led by pharmaceuticals ($137,949), followed by biotechnology ($132,576) and medical devices ($94,652). Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , ,

FierceBiotech Names 2014 Fierce 15

FierceBiotech

FierceBiotech released their much-anticipated 2014 Fierce 15 list today, their annual list of private biotech upstarts to watch. We’ll be hearing from three of them at next month’s BIO Investor Forum, October 7-8 in San Francisco: Adaptimmune and Sutro Biopharma will be making company presentations, and Editas Medicine CEO Katrine Bosley will participate as a panelist in one of our therapeutic workshops, Gene Therapy Ascending? Today’s Advancements Over Past Hurdles. Here’s the scoop on each, Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , ,